Welcome to our dedicated page for COMPUGEN SEC filings (Ticker: CGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on COMPUGEN's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into COMPUGEN's regulatory disclosures and financial reporting.
Compugen Ltd SVP of Business Development Zurit Levine exercised stock options and sold shares in a pre-planned transaction. On this Form 4, Levine exercised options to acquire 3,500 Ordinary Shares at exercise prices of $0.8292 and $1.15 per share, then sold 3,500 Ordinary Shares at $2.20 per share.
The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025, indicating they were pre-arranged. After these trades, Levine directly holds 29,375 Ordinary Shares.
COMPUGEN LTD President and CEO Ophir Eran exercised stock options and sold shares in a planned transaction. On this Form 4, he exercised options to acquire 5,625 Ordinary Shares at an exercise price of $0.8292 per share, converting a derivative position into common stock. On the same date, he sold 5,625 Ordinary Shares at a weighted average price of $2.2067 per share in open-market transactions made under a Rule 10b5-1 trading plan adopted on December 26, 2025. Following these transactions, he directly holds 11,375 Ordinary Shares and 24,375 Share Options.
COMPUGEN LTD senior vice president of business development Zurit Levine exercised stock options and sold shares in a planned transaction. She exercised options for 11,875 ordinary shares at an exercise price of $0.8292 per share, then sold 11,875 ordinary shares at a weighted average price of $2.0368 per share.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, indicating it was scheduled in advance rather than timed discretionarily. Following these transactions, Levine holds 29,375 ordinary shares directly.
CGEN affiliate filed a notice to sell 24,375 ordinary shares. The filing lists two option-originated lots: 22,375 shares from an 11/09/2022 grant and 2,000 shares from an 08/03/2023 grant, with the proposed sale date of 03/26/2026. The filing lists an aggregate amount of $50,212.50 and shows 94,553,191 shares outstanding as of 03/26/2026 as context.
Compugen Ltd director Sanford S. Zweifach reported his initial holdings, including 12,680 Ordinary Shares, which include 9,216 restricted stock units that vest over time, subject to continued service. He also holds several share options to buy Ordinary Shares at exercise prices between $1.15 and $14.40, with expirations from 2029 through 2035.
COMPUGEN LTD filed an initial ownership report for its Chief Financial Officer, David Silberman. The filing lists his current equity holdings rather than new market transactions.
He directly holds Ordinary Shares and two sets of share options over Ordinary Shares. One option covers 65,000 underlying Ordinary Shares at an exercise price of $1.6900 per share, expiring on July 31, 2034. A second option covers 24,000 underlying Ordinary Shares at an exercise price of $1.4600 per share, expiring on August 5, 2035.
Footnotes explain that these options and related RSUs vest over time starting on September 30, 2026, with the remaining portions vesting in regular quarterly installments, subject to Mr. Silberman’s continued service to the company.
Compugen Ltd director Livnat Savitzky Kinneret filed an initial ownership report showing direct holdings of ordinary shares, restricted stock units (RSUs), and stock options. She holds 13,350 ordinary shares, including 9,216 RSUs. Of these RSUs, 1,716 vest in 11 equal quarterly installments commencing on April 1, 2026, and 7,500 vest 25% on October 1, 2026 with the remainder in 12 equal quarterly installments thereafter, all subject to continued service.
The filing also lists several option awards over ordinary shares with exercise prices ranging from $1.15 to $14.40 per share and expiration dates from August 6, 2028 through August 5, 2035. These options have various vesting schedules, including grants that are fully vested and others that vested or vest 25% on specific dates such as April 1, 2023, October 1, 2024, October 1, 2025, and October 1, 2026, with remaining portions in 12 equal quarterly installments, conditioned on her continued service to Compugen.
Compugen Ltd. director Eran Perry has filed an initial Form 3 reporting his equity holdings in the company. He directly owns 10,000 Ordinary Shares and 9,216 restricted stock units, which vest in scheduled quarterly installments starting on April 1, 2026 and October 1, 2026, subject to continued service. He also holds multiple share options over Ordinary Shares with exercise prices ranging from $1.15 to $14.40 per share and expiration dates between July 1, 2029 and August 5, 2035, with portions already vested and the remainder vesting in equal quarterly installments.
Compugen Ltd’s President and CEO, Ophir Eran, filed an initial statement of ownership showing both ordinary shares and stock options in the company. He directly holds 11,375 ordinary shares, including 7,821 restricted stock units that begin vesting in 11 equal quarterly installments starting on March 31, 2026, subject to continued service. He also holds multiple share options over Compugen ordinary shares with exercise prices ranging from $0.8292 to $14.4000, expiring between 2026 and 2035, many of which vest or continue vesting in quarterly installments tied to ongoing service.